A recent Scripps Health study found that 34 patients on GLP-1 therapies (semaglutide or tirzepatide) reduced injection frequency after hitting a weight-loss plateau, with about 36 weeks of follow-up showing most maintaining weight loss, improved body composition, lower blood pressure, and better blood sugar control; a few patients did revert to weekly dosing after weight regain.

The study, published in Obesity, suggests lowering the dosing frequency to every two to three weeks could help sustain weight loss and metabolic benefits for a majority of patients.

Researchers noted that tapering to less frequent dosing was associated with maintained gains for many, though not all, and that some individuals may need to resume the original dosing pattern.

The researchers acknowledge the small, preliminary nature of the study and call for larger, randomized trials to confirm tapering viability, examine costs, side effects, and access issues for GLP-1 medications.

The authors caution that while tapering may reduce treatment burden and costs if effective, success is not universal and de-escalation may fail for some patients.

Overall, if validated, reduced-frequency GLP-1 dosing could offer a practical way to sustain benefits and lower medication costs, addressing long-term adherence challenges.

The findings hint at a potential shift toward structured de-escalation as a strategy to maintain health gains while cutting dosing frequency and cost, pending further research.

It’s noted that GLP-1 therapies can drive substantial weight loss but are costly and often cause gastrointestinal side effects, complicating long-term, frequent dosing.

Most participants maintained improvements in blood pressure, cholesterol, and glycemic control after tapering, signaling potential for long-term persistence at reduced doses.

The study aimed to see if lower-frequency GLP-1 dosing preserves results and reduces costs, but broader conclusions require larger, rigorous trials, ideally double-blind randomized controlled trials.

Post-tapering BMI largely held steady for most participants, with only five seeing slight weight regain (largest regain around eight pounds), and several even showing minor BMI reductions.

Study limitations include a small, non-diverse sample (predominantly white, privately insured, self-selected participants) and no control group, so findings are not yet definitive.